Skip to main content


Fig. 2 | Respiratory Research

Fig. 2

From: ZDHXB-101 (3′,5-Diallyl-2, 4′-dihydroxy-[1,1′-biphen-yl]-3,5′-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator of transcription-3 signaling pathways

Fig. 2

The effects of ZDHXB-101 on the OVA-induced expression of soluble epoxide hydrolase, CYP2J2 and 14,15-EETs. The protein level of soluble epoxide hydrolase (sEH) was assessed by immunohistochemistry (a-b), and the CYP2J2 and 14,15-EET levels were assessed by Western blot (c) and ELISA (d), respectively. All measurements were performed 24 h after the last challenge with treatment of ZDHXB-101 at doses of 3 mg/kg and 10 mg/kg. Scale bar: 100 μm. The data represent means ± S.D. Immunohistochemistry and ELISA assay (n = 10), Western blot (n = 6). ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. the model group

Back to article page